Your SlideShare is downloading. ×
0
3 stocks that soared stupendously this week  6-27-14
3 stocks that soared stupendously this week  6-27-14
3 stocks that soared stupendously this week  6-27-14
3 stocks that soared stupendously this week  6-27-14
3 stocks that soared stupendously this week  6-27-14
3 stocks that soared stupendously this week  6-27-14
3 stocks that soared stupendously this week  6-27-14
3 stocks that soared stupendously this week  6-27-14
3 stocks that soared stupendously this week  6-27-14
3 stocks that soared stupendously this week  6-27-14
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

3 stocks that soared stupendously this week 6-27-14

2,853

Published on

3 of this week's best-performing health-care stocks

3 of this week's best-performing health-care stocks

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
2,853
On Slideshare
0
From Embeds
0
Number of Embeds
10
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide
  • http://www.fool.com/investing/general/2014/02/04/why-furiex-pharmaceuticals-inc-shares-furiously-do.aspx
  • http://finance.yahoo.com/news/ohr-pharmaceutical-present-16th-annual-131500941.html
  • http://finance.yahoo.com/news/athenahealth-surges-stronger-expected-4q-181446268.html
  • http://investor.furiex.com/releasedetail.cfm?ReleaseID=822849
  • Transcript

    • 1. 3 Stocks That Soared Stupendously This Week
    • 2. Americans had reason to cheer this week as the U.S. advanced to the next round of the World Cup. Shareholders of these three health-care stocks cheered on also as their investments racked up massive gains.
    • 3. Shares of the clinical stage pharmaceutical firm surged 35% this week. Aerie Pharmaceuticals (NASDAQ:AERI) Source: Yahoo! Finance
    • 4. • Aerie reported great results from its phase 2b trial of roclatan • The drug, which targets treatment of glaucoma, met all clinical endpoints in the study • Roclatan performed very well on the study’s primary endpoint, reducing mean diurnal intraocular pressures by 34% • Aerie now plans to advance the drug to a late-stage clinical study Why Aerie shares went airborne
    • 5. Shares of the biotech skyrocketed 44% higher for the week. Vertex Pharmaceuticals (NASDAQ:VRTX) Source: Yahoo! Finance
    • 6. • Vertex announced positive results from two phase 3 studies • Both studies focused on use of a VX- 809/Kalydeco combo in treating cystic fibrosis • Patients taking the drug combo experienced statistically significant improvement in forced expiratory volume in one second, a respiratory measure known as FEV1 • Next steps for Vertex include filing for regulatory approval in both the U.S. and Europe Why Vertex shares vaulted higher
    • 7. Shares of the medical products supplier soared almost 97% higher this week. Medical Action Industries (NASDAQ:MDCI) Source: Yahoo! Finance
    • 8. • Owens & Minor (NYSE:OMI) announced plans to acquire Medical Action Industries • The large health-care logistics company will pay $13.80 per share – reflecting a $208 million valuation of Medical Action net of cash • Owens & Minor stated that the acquisition will create between $10 million and $12 million in cost synergies by the end of 2016 • Around 45% of Medical Action’s sales over the last year were to Owens & Minor Why Medical Action shares took off
    • 9. • Medical Action’s stock has likely seen about as much action as it’s going to get • Aerie shares could continue to perform well after the great results for roclatan • The nod for best pick, though, goes to Vertex • Vertex has a good shot of winning regulatory approval after the solid results from the phase 3 studies for its VX-809/Kalydeco combo • Some profit-taking is quite possible, but shares could resume their climb over the next few months in anticipation of approval decisions in the U.S. and Europe Best pick to keep soaring?
    • 10. Cable’s going away. But do you know how to profit? There’s $2.2 trillion at stake. Find out which 3 companies stand ready to benefit -- and they’re not Netflix, Google, and Apple!

    ×